Kornimate/medical-research-clean huggingface dataset:
role of cx3cr1-expressing cells in hematologic malignancy

Conditions: CX3CR1 Protein; Diffuse Large B Cell Lymphoma; Multiple Myeloma

Summary: this study evaluates the clinical significance of cx3cr1-expressing myeloid and lymphoid cells in patients of hematologic malignancy. tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis and lymphopoiesis. myeloid cells expressing cd11b play a critical role in sustaining cancer progression. also, the fractalkine (cx3cl1; fkn)/cx3cr1 axis plays an important function in the pathophysiology of various forms of cancers. fkn is the only known ligand for cx3cr1, and it triggers recruitment of cx3cr1-positive cells through its unique receptor, cx3cr1. therefore, the investigators focused the prognostic significance of cd11b+ myelo-monocytic cells expressing cx3cr1 and cd3+ lymphoid cells expressing cx3cr1 in the clinical outcomes of newly diagnosed diffuse large b-cell lymphoma (dlbcl) and multiple myeloma (mm).

bone marrow aspirates will be obtained from newly diagnosed mm and dlbcl patients at the time of diagnosis and relapse. peripheral blood will be obtained at the time of diagnosis, finishing treatment, 3 months after treatment and relapse. the investigators will analyze the cell fractions of cd11b+ cx3cr1+ cells and cd3+cx3cr1+ cells in blood samples by flowcytometry. the investigators will find out the relationship between the tested cells and clinical outcome in mm and dlbcl.

Eligibility criteria:
inclusion criteria: * subject newly diagnosed multiple myeloma. * subject newly diagnosed diffuse large b cell lymphoma. exclusion criteria: * history of other hematologic malignancy * history of previous chemotherapy
thin catheter for hysterosalpigography

Conditions: Infertility

Summary: hysterosalpingography is usually painful and the use of thin catheters of iui could be an attractive alternative . we conducted a randomised controlled trial to compare the standard metal cannula to the thin catheter originally manufactured for intrauterine insemination. pain assessment was done using visual analogue scale

hsg is widely practiced in our country, however, for cost effective reasons, the standard metal cannula is the only method used at our hospital. it is painful procedure because it requires grasping the cervix with a tenaculum and inducing some cervical dilatation during introduction of the cannula. the aim of this pilot study was to modify the technique of hsg using a thinner than normal catheter, and without grasping the cervix with a tenaculum. leakage of the dye through the cervix was prevented by pressing on the portiovaginalis of the cervix using the vaginal speculum.

Eligibility criteria:
inclusion criteria: * infertile women seeking evaluation of fallopian tubes exclusion criteria: * any woman with allergy to the iodine dye or condition contraindicating pregnancy

Keywords: hysterosalpingography, catheter, pain, visual analogue scale
china 3t mri study

Conditions: Bradycardia; Tachycardia; Heart Failure

Summary: the purpose of the china cied 3.0t mri performance study is to confirm safety of surescan cied in the clinical 3.0t mri environment when subjects receive mri scans. ll subjects will have required follow-up visits at baseline, mri visit, 1-month post-mri. the mri scans will occur at the mri visit. the mri scan region will be determined by investigator according to the subject's clinical condition.


Eligibility criteria:
inclusion criteria: * subjects who were implanted an surescan system cied over 6 weeks at the time of signing icf. * subjects who are able and willing to undergo elective mri scanning without sedation. * subjects who were implanted an surescan system cied in the pectoral region. * subjects who are geographically stable and available for follow-up at the study site for the length of the study. * subjects who are at least 18 years of age (or older, if required by local law). exclusion criteria: * subjects who require a legally authorized representative to obtain informed consent. * subjects with abandoned or capped leads. * subjects who require an indicated mri scan, other than those specifically described in the china cied 3.0t mri performance study, before the 1-month post-mri follow-up. * subjects with a non-mri compatible device (such as neurostimulators) or material implant (e.g., non-mri compatible sternal wires, neurostimulators, biostimulators, metals or alloys). * subjects with medical conditions that preclude the testing required by the cip or limit study participation. * subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the surescan study. co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the medtronic study manager. * female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. women of childbearing potential are required to have a negative pregnancy test within seven (7) days prior to device implant.
pilot study of fenofibrate for psc

Conditions: Primary Sclerosing Cholangitis

Summary: the purpose of this study is to determine whether fenofibrate is safe and effective in the treatment primary sclerosing cholangitis (psc).


Eligibility criteria:
inclusion criteria: * male and female patients of 18 to 75 years old * confirmed diagnosis of psc including typical findings of stricturing and dilatations of the intra and/or extrahepatic biliary ducts in radiographic exam, (endoscopic retrograde cholangiopancreatography -ercp, percutaneous cholangiogram - ptc or magnetic resonance cholangiopancreatography- mrcp) * serum alkaline phosphatase levels elevated to at least 1.5 times the upper limit of normal. exclusion criteria: * hypersensitivity to fenofibrate * prisoners and institutionalized subjects * pregnant or nursing women * anticipated need for liver transplantation in one year * recipients of liver transplantation * recurrent variceal hemorrhage, uncontrolled encephalopathy or refractory ascites * co-existing liver diseases including auto-immune and viral hepatitis * acute or chronic renal failure, defined as glomerular filtration rate (gfr)\< 60 ml/min, gfr calculated using the modification of diet in renal disease (mdrf) gfr calculator * known cholecystitis * current use of statins * current use of coumadin anticoagulant therapy * previous history of, or known high risk for, venous thromboembolism,
eus evaluation of cbd diameter in malignant obstructive jaundice

Conditions: Pancreatic Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Ampulla of Vater Cancer; Jaundice, Obstructive

Summary: the main objective of the study is to evaluate the size of the common bile duct (cbd) in a large cohort of patients with jaundice secondary to pancreatic head or distal bile duct malignancy undergoing diagnostic eus for tissue acquisition or evaluation of resectability and to establish factors associated with a dilation of the cbd greater than 15mm.

rationale: the size of the common bile duct (cbd) may influence the type of stent used and the type of the procedure performed in cases of eus-guided biliary drainage. however, no data of the size of the cbd in patients with jaundice presenting with a pancreatic head mass or with a distal cholangiocarcinoma/ carcinoma of the ampulla of vater are available. objectives: to evaluate the size of the cbd in a large cohort of patients with jaundice secondary to pancreatic head or distal bile duct malignancy undergoing diagnostic eus for tissue acquisition or evaluation of resectability and to establish factors associated with a dilation of the cbd greater than 15mm. study design: international prospective observational multicenter trial. study population: patients ≥18 years old, referred for eus-guided tissue sampling or evaluation of resectability of a pancreatic, a distal bile duct lesion or a carcinoma of the ampulla of vater determining obstructive jaundice. intervention: eus examination main study parameters/endpoints: measurement of the cbd in patients with an obstructive distal biliary mass. determine the factors associated with a cbd greater than 15mm nature and extent of the burden and risks associated with participation, benefit and group relatedness: measurement of the cbd during eus examination does not add additional risks to the procedure.

Eligibility criteria:
inclusion criteria: * patients with jaundice and a pancreatic head mass lesion referred for eus-guided tissue acquisition or staging * patients with jaundice and a distal cbd lesion suggestive of cholangiocarcinoma or a carcinoma of the ampulla of vater referred for eus-guided tissue acquisition or staging * serum bilirubin level ≥3 mg/dl * age ≥18 years * written informed consent exclusion criteria: * presence of altered anatomy from previous gastric surgery (billroth ii or roux-en-y anastomosis) * previously performed sphincterotomy, biliary plastic stent or metal stent placement * previous percutaneous drainage of the bile duct * pregnancy * inability to sign the informed consent
long-term outcome of patients treated with extracorporeal membrane oxygenation

Conditions: Long-term Outcome; Extracorporeal Membrane Oxygenation

Summary: outcomes and long-term quality-of-life of patients treated with extracorporeal membrane oxygenation are not known in china.a cross-section survey will be performed to assess the long-term outcome of these patients.

patients admitted to icus and treated with extracorporeal membrane oxygenation from march 1,2011 to march 1,2017 were screened . pre-ecmo clinical parameters(diagnose,apache-ii, sofa,indications,expected mortality) and related treatment conditions(duration of icu stay, duration of ecmo,duration of mechanical ventilation,ventilation conditions,prone ventilation,ecmo complications )will be used to assess the severity and curative effect of these patients.short form-36 health status questionnaire,euroqol-5 dimensions and st. george's respiratory questionnaire(sgrq) will deliver in these survivors ,which are used to assess the physical and mental health ,as well as the social adaptation. finally a comprehensive assessment will be obtained to describe the outcomes and long-term quality-of-life of patients treated with ecmo.

Eligibility criteria:
inclusion criteria: * patients treated with ecmo exclusion criteria: * non-survivors of patients treated with ecmo，declined or lost to follow up

Keywords: outcome,ecmo,respiratory failure,circulatory failure
safety study of dexmedetomidine in elderly under general anesthesia

Conditions: Hip Fractures; Hip Disease

Summary: the purpose of this study is to find out appropriate dose range of dexmedetomidine to provide the elderly patients satisfactory sedation and analgesia with stable hemodynamics during perioperative period of hip replacement under general anesthesia.

all patients will be screened to determine eligibility for study entry, and the patients who meet the eligibility requirements will be informed about the study and potential risks. after giving written informed consent, the patients will be randomized into different doses of dexmedetomidine groups and the comparative groups in a same ratio.

Eligibility criteria:
inclusion criteria: * age ≥65yr, american society of anesthesiologists (asa) physical status scale grade i-iii, ready for hp; body weight between 45 and 75kg, body mass index (bmi) between 18 and 24kg/m2; * the health conditions generally well according to medical history, physical examination, and laboratory tests; * no signs of difficult intubation; * no history of dementia and mental problems; * normal cognitive function, ability to understand and comply with study procedures. exclusion criteria: * age \ 90 yr; bmi greater than 24 kg/m2; asa grade higher than iii; * heart failure, severe arrhythmias, severe bradycardia (heart rate less than 40 beats/min), atrioventricular block of degree 2 or above, sick sinus syndrome, systolic blood pressure (sbp) ≥180 or \<90 mmhg, diastolic blood pressure (dbp) ≥110 or \<60 mmhg; * severe liver or kidney dysfunction, severe infection, and other pathological conditions that interfere with study results. * dementia, cerebrovascular accidents within 3 months, mental illness, epilepsy, and other adverse events that interfere with study results. * patients with the conditions that block communication and preoperative assessment, such as serious hearing or visual impairment; * history of chronic analgesic use, long-term psychotropic medication use, alcohol or drug addiction.

Keywords: dexmedetomidine elderly hemodynamics hip replacement general anesthesia
thoracic fluid content by bioimpedance-based starling system

Conditions: Acute Respiratory Distress Syndrome; Hemodynamic Instability; Shock; Fluid Overload Pulmonary Edema

Summary: the starling system is a completely non-invasive hemodynamic monitoring technique. it is able to measure the thoracic fluid content (tfc). the tfc is supposed to reflect the total content of fluid in the thorax. thus, tfc may include two of the variables that are commonly used for hemodynamic monitoring: the extravascular lung water (evlw), and the global end-diastolic volume (gedv). however, whether the tfc actually reflects gedv and evlw has not been clearly established. the objective of the study is to establish the determinants of tfc among hemodynamic variables including evlw and gedv.

the starling system is a completely non-invasive hemodynamic monitoring technique. it measures cardiac output through bioreactance. it also measures the mean transthoracic electric impedance (z0) from which the thoracic fluid content (tfc) can be derived. the tfc is the only other variable that is provided by the system besides cardiac output and that is not inferred from it. the tfc is supposed to reflect the total content of fluid in the thorax and may include two of the variables that are commonly used for hemodynamic monitoring: the extravascular lung water (evlw), which is the volume of lung edema, and the global end-diastolic volume (gedv), which is a static index of cardiac preload. cardiac preload is an important physiological variable; a prerequisite for tfc as a reflect cardiac preload would be that its changes are tightly linked to the changes in well-established markers of cardiac preload, as the gedv measured by transpulmonary thermodilution, or the central venous pressure (cvp). nevertheless, this has never been demonstrated. in addition, tfc includes the volume of evlw, which is the volume of fluid contend in the lungs outside the pulmonary vessels. nevertheless, the degree to which tfc is influenced by absolute values and changes in evlw has never been established. the objective of the study is to establish the determinants of tfc among well-known hemodynamic variables including evlw and gedv, as well the value of tfc as a marker of cardiac preload and lung water.

Eligibility criteria:
inclusion criteria: * age ≥ 18 y.o. * hospitalization in an icu * monitoring by transpulmonary thermodilution already in place * decision by clinicians in charge to perform volume expansion by saline or fluid removal by diuretics infusion and/or ultrafiltration ("fluid" group) * or presence of acute respiratory distress syndrome according to the berlin definition ("ards" group) exclusion criteria: * refusal to join the study * in "fluid" group, circulatory failure whose treatment cannot be postponed for ≥5 minutes (time required for the installation of starling system). * impossibility to paste bioreactance electrodes properly in the skin of the thorax.

Keywords: acute respiratory distress syndrome shock hemodynamic monitoring fluid balance pulmonary edema
two week cross-over study comparing two daily disposable contact lenses

Conditions: Myopia

Summary: this study seeks to evaluate and compare the clinical performance of two daily disposable soft contact lenses, proclear 1 day and 1-day acuvue moist.


Eligibility criteria:
inclusion criteria: * at least 18 years of age and no more than 39 years of age * existing soft contact lens wearers * willing to signed a written informed consent. * own a mobile phone and are willing to receive and reply to short message service (sms) messages during the day. * have a contact lens spherical distance requirement between -1.00 diopters (d) and -6.00 diopters (d) in both eyes. * have an astigmatism of 1.00d or less in both eyes. * require a visual correction in both eyes. * be correctable to a visual acuity of 6/9 (20/30) or better in each eye. * have normal eyes with no evidence of abnormality or disease that would preclude lens wear. exclusion criteria: * clinically significant (grade 3 or 4) corneal edema, corneal vascularization, tarsal abnormalities, bulbar infection, or any other abnormality of the cornea that would contraindicate contact lens wear. * clinically significant corneal staining (grade 3 in more than one region). * keratoconus or other corneal irregularity. * abnormal lachrymal secretions. * extended wear of contact lenses last 3 months. * polymethyl methacrylate (pmma) or rigid gas-permeable (rgp) lens wear in the previous 8 weeks. * refractive surgery. * eye injury/surgery within 8 weeks immediately prior to enrollment for this study. * pre-existing ocular irritation that would preclude contact lens fitting. * require concurrent ocular medication * any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. * any infectious disease (e.g., hepatitis, tuberculosis) or any immunosuppressive disease (e.g., hiv). * diabetes. * pregnant, lactating or planning a pregnancy at the time of enrollment. * participation in any concurrent clinical trial or in last 30 days.
clinicopathologic characteristics, progression, and prognostic analysis of ipnb

Conditions: Bile Duct Neoplasms Malignant

Summary: the main aim of this observational study is to understand the clinicopathological and prognostic information of ipnb, a rare tumor. the participants have already received treatment during their previous routine medical management and took part in follow - up. we will look into their survival information after previous medical visits and treatment.


Eligibility criteria:
inclusion criteria: * ipnb with or without malignant transformation was confirmed by pathological examination exclusion criteria: * missing other essential clinical data * coexisting malignant tumors of other digestive system organs

Keywords: intraductal papilloma of bile duct malignancy progression risk factors prognosis
intracranial pressure in monopolar and bipolar hysteroscopy

Conditions: Intracranial Pressure Increase

Summary: two distinction fluids are used in operative hysteroscopy. one is monopolar and the second is bipolar. the monopolar fluid contains mannitol and the bipolar fluid contains serum physiologic. this study aims to compare intracranial pressure in patients undergoing monopolar and bipolar hysteroscopy.

operative hysteroscopy is currently used in the treatment of several diseases including submucosal myomas, polyps, uterine septum, and abnormal intrauterine bleeding. two different methods for distension of the uterus for hysteroscopy are available currently. one is monopolar and the second is bipolar. the monopolar fluid contains mannitol and the bipolar fluid contains serum physiologic. passage of the distention fluid into the uterine veins during hysteroscopy might lead to volume overload, water intoxication, hyponatremia, pulmonary edema or brain edema. however, the effect of monopolar hysteroscopy or bipolar hysteroscopy on intracranial pressure in patients undergoing hysteroscopy is unknown. optic nerve sheath diameter (onsd) measurement is a surrogate marker of invasive intracranial pressure. this study aims to compare the impact of monopolar and bipolar hysteroscopy on intracranial pressure by using onsd measurement in patients undergoing hysteroscopy.

Eligibility criteria:
inclusion criteria: * must be scheduled to hysteroscopy for treatment of uterine myoma, polyp, septum, or for endometrial ablation. exclusion criteria: * postmenopause; * kidney disease; * cardiovascular disease; * glaucoma
the effect of repetitive transcranial magnetic stimulation (rtms) on depression in parkinson's disease (pd)

Conditions: Depression in Parkinson's Disease

Summary: this study aims to assess the therapeutic role of rtms on parkinson's patients with depression. patients diagnosed with parkinson's disease and depression will be recruited. all patients will be admitted and will be allocated randomly into two groups one of which will receive real sessions of high frequency rtms for left dorsolateral prefrontal cortex (dlpfc) for 10 consecutive sessions totally over period of 10 days with repeated booster sessions every month during the period of follow up. the other will receive sham sessions.

this study aims to assess the therapeutic role of rtms on parkinson's patients with depression. thirty pd patients with depression using united kingdom (uk ) bank criteria for pd will be recruited from outpatient clinic in assiut university. all patients will be admitted at neuropsychiatric department, assiut university hospital/ assiut, egypt.each patient fulfilled the inclusion criteria as having score more than or equal 14 on beck depression inventory (bdi) will be recruited. the patients will be allocated randomly into two groups one of which will receive real sessions of high frequency rtms (25 hz), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for left dlpfc for 10 consecutive sessions totally over period of 10 days with repeated booster session every month during the period of follow up among three months. the other will receive sham sessions. all subjects will be followed up by selected clinical rating scales at different intervals pre session, post 10 sessions, and after one, two and three months.

Eligibility criteria:
inclusion criteria: * all patients with parkinson's disease who were diagnosed according to uk bank criteria for pd, aged 45-75 years, with criteria for depression (bdi \> or = 14), and consent obtained from the patient or his caregiver. exclusion criteria: * history of repeated head injury * history of repeated cerebrovascular strokes * history of defined encephalitis * oculogyric crisis, supranuclear gaze palsy * family history of more than one relative * history of drug intake as antipsychotics or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) exposure * moderate and severe depression (hamilton depression rating scale score \>16) * severe dysautonomia * cerebellar signs * babinski sign * strictly unilateral features after 3 years * hydrocephalus or intracranial lesion on neuroimaging * we also excludes patients with intracranial metallic devices or with pacemakers or any other device. * patients with cognitive impairment (mini-mental status examination\< 24)